Compare AstraZeneca plc (AZN) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Oracle Corporation — how do they compare? AstraZeneca plc trades at $168.5 (market cap $253.13B), while Oracle Corporation trades at $132.66 (market cap $368.53B). The key difference: Oracle Corporation is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | ORCL | |
|---|---|---|
Market Cap | $253.13B | $368.53B |
Sector | Health | Technology |
52-Week High | $209.48 | $328.33 |
52-Week Low | $137.44 | $127.96 |
Enterprise Value | $279.37B | $497.78B |
Dividend Yield | 1.92% | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Oracle (ORCL) trades at $131.86, down 6.27% in the last 24 hours, amid a bearish technical signal but strong fundamental performance. The company reported revenue of $57.40B in 2025 with a net income margin of 25.37%, and has beaten earnings estimates for the last three quarters. Recent news highlights Oracle's AI infrastructure growth and a pending Q2 2026 earnings report on June 10, 2026.
The outlook for Oracle is positive due to robust earnings growth and AI-driven opportunities, though risks include high debt levels and competitive pressures. Analysts maintain a bullish consensus with a $259 price target, suggesting significant upside from the current price if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
